RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction
JAMA Cardiology
JUNE 17, 2024
This genetic association study evaluated genetic variants associated with increased risk of vasospastic angina.
Angina Related Topics 
Cold weather = worse angina symptoms!
Heart Sisters
JANUARY 28, 2024
If you live with heart disease, it’s important to know the surprising effects of COLD TEMPERATURES on your heart health.
Angina 
125
125 
Recurrent polymorphic ventricular tachycardia without chest pain: an unusual presentation of focal coronary artery spasm
The British Journal of Cardiology
MARCH 4, 2025
Coronary artery spasm (CAS), or Prinzmetal angina, is a recognised cause of myocardial ischaemia in non-obstructed coronary arteries which typically presents with anginal chest pain. This case report describes an atypical presentation of CAS in a 68-year-old white British male with cardiovascular risk factors.
Chest Pain 73
73 
Familial risk of vasospastic angina: a nationwide family study in Sweden
Open Heart
DECEMBER 6, 2023
Objectives Vasospastic angina (VSA) is a complex coronary vasomotor disorder associated with an increased risk of myocardial infarction and sudden death. Despite considerable advances in understanding VSA pathophysiology, the interplay between genetic and environmental factors remains elusive.
Angina 96
96 
Acupuncture combined with multiple therapies for angina pectoris: a systematic review and network meta-analysis
Frontiers in Cardiovascular Medicine
JANUARY 29, 2025
ObjectiveAcupuncture combined with multiple treatment modalities has been widely employed for treating angina pectoris. This paper compared the efficacy of acupuncture combined with multiple treatment modalities for angina pectoris by network meta-analysis (NMA).MethodsAs and Stata (version 16.0).Results46
Angina 64
64 Angina 64
64 
Causal Relationship Observed Between Angina Pectoris and Gout Onset
HCPLive
MAY 6, 2024
The meta-analysis demonstrated gout with high blood uric acid levels significantly increases the risk of experiencing angina attacks.
Angina 59
59 Angina 59
59 
Optimizing Management of Stable Angina: Key Points
American College of Cardiology
AUGUST 14, 2024
The following are key points to remember from a state-of-the-art review on optimizing management of stable angina.
Angina 53
53 
Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
American College of Cardiology
DECEMBER 21, 2023
The goal of the ORBITA-2 trial was to assess the efficacy of percutaneous coronary intervention (PCI) compared with a sham placebo procedure for angina relief among patients with stable angina who were not on background antianginal medication.
Angina 60
60 
Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial
Frontiers in Cardiovascular Medicine
JANUARY 28, 2025
Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P=0.013) and a reduction in the frequency of angina episodes (P=0.021).
Case Report: Vasospastic angina presenting as phantom odor perception
Frontiers in Cardiovascular Medicine
JULY 5, 2024
BackgroundVasospastic angina usually presents with intermittent episodes of chest pain. The patient was started on calcium channel blocker therapy with resolution of symptoms.ConclusionPhantom odor perception has been rarely reported as an angina-equivalent symptom.
Angina 52
52 
ORBITA-2: Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
American College of Cardiology
JUNE 6, 2024
The ORBITA-2 (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial data demonstrate that, in patients with stable angina and ischemia producing coronary stenoses.
Angina 53
53 
Efficacy and safety of tongxinluo capsule for angina pectoris of coronary heart disease: an overview of systematic reviews and meta-analysis
Frontiers in Cardiovascular Medicine
FEBRUARY 12, 2024
Background Tongxinluo capsule (TXLC) is a common drug for treating angina pectoris of coronary heart disease (CHD). In recent years, many systematic reviews (SRs) and meta-analyses (MAs) have reported the efficacy and safety of TXLC for improving angina symptoms in patients with CHD.
Angina 64
64 
ORBITA 2: The power of PCI revealed for stable angina
Cardiology Update
NOVEMBER 19, 2023
The ORBITA-2 trial ( NCT03742050 ) investigated the efficacy of Percutaneous Coronary Intervention (PCI) compared to placebo in 301 patients with stable angina. At the 12-week mark, the PCI group exhibited a significantly lower mean angina score (2.9) compared to the placebo group (5.6; odds ratio, 2.21; 95% CI, 1.41-3.47;
Angina 52
52 
Coronary Sinus Implant Proves Symptom Relief Benefit in Refractory Angina
Med Page Today
APRIL 8, 2024
(MedPage Today) -- ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant showed a symptom alleviation benefit in the small placebo-controlled ORBITA-COSMIC trial. The number of.
Angina 52
52 
Case Report: A case report of myocardial fibrosis activation assessment after unstable angina using 68Ga-FAPI-04 PET/CT
Frontiers in Cardiovascular Medicine
JANUARY 22, 2024
However, there is a notable absence of data regarding patients with short-term myocardial ischemia, such as those experiencing unstable angina (UA). Following vascular recanalization therapy and regular medication treatment, the patient remained free of angina recurrence. The results demonstrated tracer-specific uptake (SUVmax = 4.6)
Angina 69
69 ORBITA-COSMIC: Coronary Sinus Reducer Relieves Angina, Without Increased Blood Flow to Heart
American College of Cardiology
APRIL 8, 2024
A coronary sinus reducer (CSR) may lead to a significant reduction in the number of angina episodes in patients with chronic chest pain, but it was not superior to a placebo device for improving myocardial blood flow, according to the results of the ORBITA-COSMIC study, presented during a Late-Breaking Clinical Trial session at ACC.24
Angina 56
56 
A Novel Device for Coronary Microvascular Dysfunction and Refractory Angina
NEJM Journal Watch - Cardiology
JANUARY 22, 2025
The coronary sinus reducer, approved in Europe, appears to improve angina and quality of life in patients with CMD or refractory angina.
Angina 45
45 
Percutaneous coronary intervention versus medical therapy in stable angina: a matched cohort study
Heart BMJ
APRIL 25, 2024
Objective It is uncertain whether percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT) can reduce adverse clinical events in the long term as compared with OMT alone in patients with pure stable angina. Methods We enrolled patients from 2006 to 2010 using the Korean national insurance data.
Angina 52
52 
PCI for stable angina : Sham trials are welcome, but not OMT shaming trials !
Dr. S. Venkatesan MD
SEPTEMBER 23, 2024
After a series of experiments in animals and peripheral vessels, he proved with a single patient N-1 study that effectively treated refractory LAD angina in a 38-year-old man in 1977. No one has questioned the efficacy of PCI for true angina with a critical lesion. Within a span of five to ten years, the concept spread globally.
Angina 52
52 
Comparison of various calcium antagonist on vasospastic angina: a systematic review
Open Heart
JANUARY 12, 2023
It causes stable angina to ACS. Diltiazem was found to decrease angina and increase quality of life until 12th week of treatment; however, some adverse effects include atrioventricular block and recurrent angina up till 4th week were found. Nevertheless, several CCBs adverse effects are harmful for these patients.
Angina 52
52 
A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina
Frontiers in Cardiovascular Medicine
MARCH 17, 2024
Background Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD).
Angina 64
64 
Exercise ECGs Highly Specific for Coronary Microvascular Dysfunction
Med Page Today
JANUARY 8, 2024
(MedPage Today) -- Exercise electrocardiographic (ECG) stress tests appeared to reliably indicate that some patients with angina with nonobstructive coronary arteries (ANOCA) actually had coronary microvascular dysfunction (CMD), preliminary evidence.
Exercise 120
120 
Does the Coronary Sinus Reducer Decrease Ischemia and Angina in Patients with Stable Coronary Disease?
NEJM Journal Watch - Cardiology
APRIL 10, 2024
In a randomized, controlled trial, the device reduced daily angina but not myocardial ischemia in patients with refractory angina.
Angina 45
45 
Gene Therapy Allowing Heart to Grow New Blood Vessels Supported by Early Data
Med Page Today
MAY 3, 2024
(MedPage Today) -- LONG BEACH, Calif. -- A gene therapy for therapeutic angiogenesis showed promise for people with angina who had already exhausted their options for medical therapy and coronary revascularization, according to the single-arm.
Angina 111
111 Angina 111
111 
Clinical development and proof of principle testing of new regenerative vascular endothelial growth factor-D therapy for refractory angina: rationale and design of the phase 2 ReGenHeart trial
Open Heart
OCTOBER 17, 2024
Background Despite tremendous therapeutic advancements, a significant proportion of coronary artery disease patients suffer from refractory angina pectoris, that is, quality-of-life-compromising angina that is non-manageable with established pharmacological and interventional treatment options.
Angina 52
52 
Ischemia with no obstructed coronary arteries and microvascular testing procedures: a review of utility, pharmacotherapy, and current challenges
Frontiers in Cardiovascular Medicine
FEBRUARY 17, 2025
Ischemia with no obstructive coronary arteries (INOCA) is an increasingly recognized condition in patients presenting with angina and positive stress tests but without significant coronary artery stenosis.
Ischemia 52
52 
Lumbar disc herniation is an independent predictor of plaque burden in the patients with unstable angina
Frontiers in Cardiovascular Medicine
FEBRUARY 8, 2024
Methods In this study, a total of 212 patients (age 46–80 years) with unstable angina (UA) who underwent coronary angiography (CAG) in our hospital from January 2018 to July 2022 due to UA were included. Objective Assessing the impact of lumbar disc herniation (LDH) on the plaque burden of coronary atherosclerosis is our objective.
Plaque 59
59 
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
DAIC
MAY 2, 2024
Results from the open label roll-in cohort of patients having chronic myocardial ischemia with refractory angina showed an average increase in exercise tolerance of 107 seconds and an average of 82% reduction in angina episodes at the primary six-month follow-up endpoint compared to before receiving the study treatment.
Ischemia 95
95 
Cost-effectiveness in diagnosis of stable angina patients: a decision-analytical modelling approach
Open Heart
APRIL 4, 2022
Objective Given recent data on published diagnostic accuracies, this study sought to determine the most cost-effective diagnostic strategy for detection of significant coronary artery disease (CAD) in stable angina patients using invasive coronary angiography (ICA) and fractional flow reserve (FFR) as the reference standard.
Angina 52
52 
EM Quick Hits 5 Ludwig’s Angina, Transient Monocular Vision Loss, D-dimer for PE Workup in Pregnancy, Pediatric Nasal Foreign Bodies, Trimethoprim Drug Interactions, Airway Management in Cardiac Arrest
ECG Cases
JUNE 4, 2019
The post EM Quick Hits 5 Ludwig’s Angina, Transient Monocular Vision Loss, D-dimer for PE Workup in Pregnancy, Pediatric Nasal Foreign Bodies, Trimethoprim Drug Interactions, Airway Management in Cardiac Arrest appeared first on Emergency Medicine Cases.
Changing the Orbit around Percutaneous Coronary Intervention for Stable Angina
The New England Journal of Medicine
DECEMBER 20, 2023
The primary aim of treating patients with stable angina is to decrease symptoms and improve quality of life. Percutaneous coronary intervention (PCI), a treatment for patients with angina, does not reduce the risk of death from any cause, death from cardiac causes, or myocardial infarction.1 1 In this issue.
Angina 40
40 ORBITA-STAR: Similarity Score of Induced Angina Symptoms Predicts Post PCI Improvement
American College of Cardiology
MAY 20, 2024
The closer the similarity between patient-reported and medically induced angina symptoms, the more likely these symptoms will be improved following PCI, according to ORBITA-STAR, an n-of-1 placebo-controlled study presented at EuroPCR 2024.
Angina 40
40 
A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina
The New England Journal of Medicine
NOVEMBER 10, 2023
In a randomized trial of PCI in patients with stable angina who were receiving little or no antianginal medication and had documented ischemia, PCI resulted in a better health status with respect to angina than placebo at 12 weeks.
Angina 40
40 
Abstract 4122256: Health Status Outcomes of Nicorandil in Patients With Angina Pectoris: A Prospective, Multicenter, Registry-Based Study
Circulation
NOVEMBER 11, 2024
Approximately half of patients with CAD initially present with angina pectoris. The primary outcome was the Seattle Angina Questionnaire summary score (SAQ-SS) changes from baseline to 12 months. The primary outcome was the Seattle Angina Questionnaire summary score (SAQ-SS) changes from baseline to 12 months.
Angina 40
40 
The coronary sinus reducer improves angina symptoms in patients with stable CAD
Nature Reviews - Cardiology
APRIL 24, 2024
Nature Reviews Cardiology, Published online: 25 April 2024; doi:10.1038/s41569-024-01033-x Findings from the ORBITA-COSMIC trial show that treatment of patients with stable coronary artery disease using a coronary sinus reducer improves angina symptoms but does not increase transmural myocardial perfusion.
Angina 40
40 
Enhanced External Counterpulsation for the Treatment of Angina With Nonobstructive Coronary Artery Disease
The American Journal of Cardiology
DECEMBER 13, 2023
Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): Namrita D. Ashokprabhu, Jessie Fox, Timothy D. Henry, Christian W. Schmidt, Darlene Tierney, Julie Gallatin, Yulith Roca Alvarez, Lauren Thompson, Michelle Hamstra, Sachin A. Shah, Odayme Quesada
Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial
Circulation
OCTOBER 5, 2023
BACKGROUND:We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries.METHODS:Outpatients referred for coronary computed tomography angiography in 3 hospitals in the United Kingdom were prospectively screened. Circulation, Ahead of Print. versus 50.9%,P<0.001).At
Angina 40
40 
CT test simulates blood flow to assess risk in patients with angina
Science Daily - Heart Disease
SEPTEMBER 12, 2023
An advanced CT test can identify individuals with stable angina at a reduced risk of three-year adverse outcomes despite their having a high coronary artery calcium score, according to a new study.
Angina 40
40 
Responders to PCI for Angina Relief Identified by Chest Pain Type
Med Page Today
MAY 19, 2024
(MedPage Today) -- PARIS -- Whether a person had chest pains resolved by angioplasty hinged on the nature, not the severity, of their presenting symptoms, an ORBITA-2 analysis showed. Investigators found two groups more likely to benefit from.
Chest Pain 59
59 
Coronary Sinus Narrowing Improves Coronary Microcirculation Function in Patients With Refractory Angina: A Multicenter Prospective INROAD Study
Circulation: Cardiovascular Interventions
JANUARY 15, 2024
The present study aims to investigate whether coronary sinus narrowing improves the indexes of coronary microcirculatory function.METHODS:Patients with refractory angina who had a clinical indication for reducer implantation underwent invasive physiological assessments before and 4 months after the procedure.
Angina 40
40 
Decoding the Menace Within: Unraveling Myocardial Bridges and Exercise-Induced Ischemia
Cardiology Update
JANUARY 14, 2024
The perplexing landscape of angina with nonobstructive coronary arteries (ANOCA) encompasses diverse pathophysiological entities, including coronary microvascular disease (CMD), coronary artery spasm, and the enigmatic myocardial bridging (MB).
Exercise 119
119 
Instructors' Collection ECG: Regular Really Wide QRS Tachycardia
ECG Guru
MARCH 6, 2024
Ntg is presumably sublingual nitroglycerine used for angina. So, we can assume the patient was probably being treated for angina, heart failure, and hypertension. Lasix (furosemide) is a potassium – wasting diuretic. Capoten (captopril) is an ACE inhibitor. Procardia (nifedipine) is a calcium-channel blocker.
Tachycardia 98
98 
Abstract 4144084: Enhanced External Counterpulsation as a Novel Treatment for Heart Transplant Candidates with Ischemic Heart Failure with Reduced Ejection Fraction
Circulation
NOVEMBER 11, 2024
It is primarily indicated for refractory angina that is not amenable to PCI or CABG with the opinion of a cardiologist. Despite being a heart transplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations.
In Which Patients Will PCI Relieve Angina?
Circulation
OCTOBER 26, 2024
Circulation, Ahead of Print.
Angina 45
45 
Let's personalize your content